News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Construction of the plant will commence in 2025 with first production expected to be in 2027
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Subscribe To Our Newsletter & Stay Updated
